Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JMJD6 | Q6NYC1 | 15/20 | 0.62 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | KDM6B | O15054 | 1/20 | 0.45 |
| ▸ | KDM5C | P41229 | 1/20 | 0.45 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.45 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.45 |
| ▸ | KDM3A | Q9Y4C1 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3442381 | 0.92 | JMJD6 (0.61) | JMJD6PIK3CAMEN1NPC1RAB9A | |
| SCHEMBL13119710 | 0.88 | JMJD6 (0.66) | JMJD6PIK3CAMEN1NPC1RAB9A | |
| SCHEMBL2688111 | 0.85 | JMJD6 (0.68) | JMJD6PIK3CAMEN1NPC1RAB9A | |
| SCHEMBL811785 | 0.85 | JMJD6 (0.76) | JMJD6PIK3CAKDM4EKDM6BKDM5C | |
| SCHEMBL30171421 | 0.85 | JMJD6 (0.76) | JMJD6PIK3CAKDM4EKDM6BKDM5C | |
| SCHEMBL13400616 | 0.85 | JMJD6 (0.62) | JMJD6PIK3CAMEN1NPC1RAB9A | |
| SCHEMBL16139799 | 0.84 | JMJD6 (0.51) | JMJD6PIK3CAMEN1NPC1RAB9A | |
| SCHEMBL13400614 | 0.82 | KDM5B (0.56) | JMJD6KDM4EKDM6BKDM5CKDM4C | |
| SCHEMBL6419056 | 0.82 | JMJD6 (0.53) | JMJD6PIK3CAKDM4EKDM6BKDM5C | |
| SCHEMBL28332640 | 0.80 | JMJD6 (0.61) | JMJD6PIK3CAKDM4EKDM6BKDM5C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100101643-A1 | COMPOUND, PHOTOELECTRIC CONVERTER AND PHOTOELECTROCHEMICAL CELL | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-04-29 | — | — | US | disclosed |
| US-20100101643-A1 | COMPOUND, PHOTOELECTRIC CONVERTER AND PHOTOELECTROCHEMICAL CELL | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100101643-A1 | COMPOUND, PHOTOELECTRIC CONVERTER AND PHOTOELECTROCHEMICAL CELL | CRY1, CRY2, CCNA1 | JMJD6 1632/4885PIK3CA 1214/4885MEN1 506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.